Paras Biopharmaceuticals Finland Oy provides investors with a great opportunity for an exciting and rewarding partnership

Paras Biopharmaceuticals Finland Oy offers investors a great opportunity for an exciting and rewarding partnership in addition to the opportunity to participate in a unique business opportunity.
The management of Paras Biopharmaceuticals Finland Oy brings together key skills, a technology platform and intellectual capital for four soon to be off-patent blockbuster biosimilar drugs.
Anti-diabetic products are currently a “high demand high growth area” which presents an immediate opportunity especially when a $26 billion market is expected to be open due to off-patent products by 2015.
Paras Biopharmaceuticals Finland Oy's strategy is to create a healthy pipeline of products based on its technology platform and use this foundation for further offerings of therapeutic mAbs fragments that will come out of patent between 2016-2020 and beyond.
Paras Biopharmaceuticals Finland Oy provides an excellent opportunity for value creation and is currently in active discussions for technology out-licensing in Asia, GCC countries, Africa, Russia and CIS countries, Europe and the USA.

Company Presentation 2018

Company Presentation 2016

Company Presentation 2014

Company Presentation 2012

Meet Us At

Connect with us

Paras Biopharmaceuticals
Finland Oy

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
P: +358 (0) 400207380

Dr Upendra Khurana
P:+358 (0) 449783160

Dr Mark Jackson
P:+358 (0) 442905993

Skype: Paras.Finland